Among these features, tumor cell expression of programmed death-ligand 1 (PD-L1), tumor mutation burden (TMB), presence of mismatch repair deficiency (dMMR), or high microsatellite instability (MSI-H) have found broad clinical application and are used to identify patients likely to benefit from ICIs [18]. The gene discussed is CD274; the disease is neoplasm.